Dosage and administration
of MONJUVI + lenalidomide

  • MONJUVI (tafasitamab-cxix) should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage IRRs1

  • The recommended dose of MONJUVI is 12 mg/kg based on actual body weight administered as an intravenous infusion according to the dosing schedule in the table below1

  • Administer MONJUVI in combination with lenalidomide 25 mg orally on days 1 to 21 of each 28-day cycle for a maximum of 12 cycles, then continue MONJUVI as monotherapy until disease progression or unacceptable toxicity1

  • Refer to the lenalidomide prescribing information for lenalidomide dosage and recommendations1

  • Administer MONJUVI as an intravenous infusion1

    • For the first infusion, use an infusion rate of 70 mL/h for the first 30 minutes, then, increase the rate so that the infusion is administered within 1.5 to 2.5 hours1
      — In the L-MIND study, after the first 30 minutes, the rate of infusion was increased to 125 mL/h over a 2-hour period2

    • Administer all subsequent infusions within 1.5 to 2 hours1

    • In the L-MIND study, vital signs were measured immediately prior to infusion, at 15 minutes (+/- 5 minutes), 30 minutes (+/- 10 minutes), every 60 minutes (+/- 15 minutes), and at the end of the infusion (+/- 20 minutes)2

The cycle length for MONJUVI is 28 days1
Scroll
to see
more
                                                         
Cycle 1                                                        
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
MONJUVI 12 mg/kg
Lenalidomide 25 mg daily
                                                         
Cycles 2 and 3                                                        
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
MONJUVI 12 mg/kg
Lenalidomide 25 mg daily
                                                         
                                                         
Cycles 4 to 12                                                        
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
MONJUVI 12 mg/kg
Lenalidomide 25 mg daily
                                                         
After 12 cycles, continue MONJUVI                                                        
monotherapy until disease progression                                                        
or unacceptable toxicity                                                        
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
MONJUVI 12 mg/kg
                                                         
After 12 cycles, continue MONJUVI monotherapy until disease progression or unacceptable toxicity
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
MONJUVI 12 mg/kg
                                                         
  • 45.7% of patients (37/81) had at least one dose reduction of lenalidomide3
  • 77.5% of patients (62/81) were able to receive a lenalidomide dose of ≥20 mg/day over the duration of their treatment3

Recommended premedications1

Administer premedications 30 minutes to 2 hours prior to starting MONJUVI infusion to minimize IRRs. Premedications may include acetaminophen, histamine H1 receptor antagonists, histamine H2 receptor antagonists, and/or glucocorticosteroids.

For patients not experiencing IRRs during the first 3 infusions, premedication is optional for subsequent infusions.

If a patient experiences an IRR, administer premedications before each subsequent infusion.

IRR=infusion-related reaction.


For details on dosage modifications and management of adverse reactions for IRRs and myelosuppression, please refer to the full Prescribing Information.

For more information about the storage and handling of MONJUVI and how MONJUVI is supplied, please refer to the full Prescribing Information.

  1. MONJUVI is the only CD19-targeted therapy administered in your office or clinic following 1 prior line of therapy1

MONJUVI Preparation and Administration Video

HELP PATIENTS TRACK UPCOMING APPOINTMENTS

CREATE TREATMENT SCHEDULE

MECHANISM OF ACTION

View MOA

REFERENCES: 1. MONJUVI Prescribing Information. Boston, MA: MorphoSys. 6/2021. 2. Salles G, Duell J, Gonzáles Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. doi:/10.1016/S1470-2045(20)30225-4. 3. Data on file. CSR. MorphoSys. Boston, MA.